Govt working to select locations for bulk drug, medical device parks

Union Cabinet on March 12 had approved scheme for development of three bulk drug and four medical device parks

medicine, drugs, pharma
This is being done in order to encourage domestic production of critical APIs
Press Trust of India
2 min read Last Updated : Jul 13 2020 | 9:12 PM IST
The government on Monday said it is finalising guidelines for selection of locations of upcoming bulk drug and medical device parks in the country.

"Department of Pharmaceuticals is finalising guidelines, which will form the basis for objectively selecting locations of upcoming three bulk drugs parks and four medical devices parks in the country,"Minister of Chemicals & Fertilisers DV Sadananda Gowda said.

Union Cabinet on March 12, 2020 had approved scheme for development of three bulk drug and four medical device parks, in which the government will extend grants-in-aid to states with a maximum limit of Rs 1,000 crore per bulk drug park and Rs 100 crore per medical device parks, the Ministry of Chemicals & Fertilizers said in a statement.

This is being done in order to encourage domestic production of critical APIs (active pharmaceutical ingredients)/ KSM (key starting material) and medical devices, it added.

In addition,the government has also announced, "a production linked incentive (PLI) scheme for promoting domestic manufacturing of key critical starting materials/drug intermediates & APIs and medical devices across the country," the statement said.

Total financial implications of these schemes would be about Rs 13,760 crore, it added.

"The scheme for promotion of bulk drug park is expected to result in incremental production of bulk drugs worth about Rs 46,400 crore, while scheme for promotion of medical device park will lead to incremental production of medical devices worth about Rs 68,437 crore," the ministry said.

These schemes will also result in significant generation of jobs, it added.

Development of these parks will not only reduce the country's dependence on imports but will also be helpful in making India a major player in global pharma exports, Gowda had earlier said.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Indian Pharmaceuticals IndustryNarendra Modi governmentdrugs

Next Story